These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 33330122)

  • 21. Microbe-microbe interactions during Clostridioides difficile infection.
    Abbas A; Zackular JP
    Curr Opin Microbiol; 2020 Feb; 53():19-25. PubMed ID: 32088581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention and treatment of
    Eliakim-Raz N; Bishara J
    Hum Vaccin Immunother; 2019; 15(6):1453-1456. PubMed ID: 29781761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

  • 24.
    Kester JC; Brubaker DK; Velazquez J; Wright C; Lauffenburger DA; Griffith LG
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic-Induced Alterations of the Murine Gut Microbiota and Subsequent Effects on Colonization Resistance against Clostridium difficile.
    Schubert AM; Sinani H; Schloss PD
    mBio; 2015 Jul; 6(4):e00974. PubMed ID: 26173701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.
    Dieterle MG; Rao K; Young VB
    Ann N Y Acad Sci; 2019 Jan; 1435(1):110-138. PubMed ID: 30238983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance.
    Ferreyra JA; Wu KJ; Hryckowian AJ; Bouley DM; Weimer BC; Sonnenburg JL
    Cell Host Microbe; 2014 Dec; 16(6):770-7. PubMed ID: 25498344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current understanding of antibiotic-associated dysbiosis and approaches for its management.
    Kesavelu D; Jog P
    Ther Adv Infect Dis; 2023; 10():20499361231154443. PubMed ID: 36860273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbiota-based markers predictive of development of Clostridioides difficile infection.
    Berkell M; Mysara M; Xavier BB; van Werkhoven CH; Monsieurs P; Lammens C; Ducher A; Vehreschild MJGT; Goossens H; de Gunzburg J; Bonten MJM; Malhotra-Kumar S;
    Nat Commun; 2021 Apr; 12(1):2241. PubMed ID: 33854066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The microbiota and infectious diarrhea].
    Surawicz CM
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 1():S29-36. PubMed ID: 20889002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral antibiotic use and chronic disease: long-term health impact beyond antimicrobial resistance and
    Queen J; Zhang J; Sears CL
    Gut Microbes; 2020 Jul; 11(4):1092-1103. PubMed ID: 32037950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Modulation of gut microbiota during alleviation of antibiotic-associated diarrhea with Zingiberis Rhizoma].
    Zhang XQ; Zhang CE; Yu XH; Ma YQ; Li M; Duan XY; Ma ZJ
    Zhongguo Zhong Yao Za Zhi; 2022 Mar; 47(5):1316-1326. PubMed ID: 35343160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotics, obesity and the link to microbes - what are we doing to our children?
    Turta O; Rautava S
    BMC Med; 2016 Apr; 14():57. PubMed ID: 27090219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of a sequencing-based clinical intestinal screening test in patients at high-risk for Clostridium difficile and other pathogens: a case report.
    Hitschfeld M; Tovar E; Gupta S; Bik EM; Palmer C; Hoaglin MC; Almonacid DE; Richman J; Apte ZS
    J Med Case Rep; 2019 Jan; 13(1):9. PubMed ID: 30642394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbiota-accessible carbohydrates suppress Clostridium difficile infection in a murine model.
    Hryckowian AJ; Van Treuren W; Smits SA; Davis NM; Gardner JO; Bouley DM; Sonnenburg JL
    Nat Microbiol; 2018 Jun; 3(6):662-669. PubMed ID: 29686297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotics as both friends and foes of the human gut microbiome: The microbial community approach.
    Nogueira T; David PHC; Pothier J
    Drug Dev Res; 2019 Feb; 80(1):86-97. PubMed ID: 30370682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microbiologic factors affecting Clostridium difficile recurrence.
    Chilton CH; Pickering DS; Freeman J
    Clin Microbiol Infect; 2018 May; 24(5):476-482. PubMed ID: 29208562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
    Stecher B
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.